Looking ahead to IMS 2026: The sessions I don’t want to miss
Published:
With so much to choose from at IMS 2026, some sessions have particularly caught my attention. From questions around first-relapse treatment and maintenance to blood-based monitoring, outpatient dosing and in vivo CAR-T, these are the presentations I’m most looking forward to hearing.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?